Page 2 - Event Free Survival News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STS to Present Late-Breaker Research at 2024 Annual Meeting

STS to Present Late-Breaker Research at 2024 Annual Meeting
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesPerioperative pembrolizumabCenters for medicareSociety of thoracic surgeonsMedicaid servicesSociety of thoracic surgeonThoracic surgeonsThoracic surgeons general surgeryThoracic surgery databaseTranscatheter aortic valve replacementThoracic surgeons adult cardiac surgery databasePractice guidelinesSurgical treatmentAtrial fibrillationKey takeaways

The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San A

San antonioUnited statesPerioperative pembrolizumabSociety of thoracic surgeonCenters for medicareSociety of thoracic surgeonsMedicaid servicesThoracic surgeonsThoracic surgeons general surgeryThoracic surgery databaseTranscatheter aortic valve replacementThoracic surgeons adult cardiac surgery databasePractice guidelinesSurgical treatmentAtrial fibrillationKey takeaways

Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

San antonioUnited statesPeter schmidBarts breast cancer centreEastern cooperative oncology groupCentre of eandOncology nursingAntonio breast cancerCancer medicineAntonio breast cancer symposiumEvent free survivalTriple negative breast cancerHigh riskEarly stage triple negative breast cancerKeynote 522Neoadjuvant pembrolizumab

Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.

International prognostic indexLargeb cell lymphomaB cell lymphomaCart cell therapyLymphoma treatmentResponse rateEvent free survivalDouble hit lymphomaTriple hit lymphomaZuma 7Belinda trialTransform trialAutologous stem cell transplantFirst line therapyR chopHigh risk lymphoma

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)

BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew zealandExchange commissionDrug administrationEuropean medicines agencyEuropean society for medical oncologyBeigene ltdEuropean commissionProduct serviceGene announcesMet primary endpointsMajor pathological response rateEvent free survivalResectable non small cell lung cancerBlinded independent pathology reviewBlinded independent central review